Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) Growth (3y) (2020 - 2026)
Kiniksa Pharmaceuticals International (KNSA) EPS (Basic) Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.31 Bn | 43.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.86 Bn | 40.20 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 32.13 Bn | 30.45 Bn | 1.05 Bn | 3.18% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.84 Bn | 5.10 Bn | 2.42% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 12.25% |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -35.06% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 13.47% |
| 8 | Elanco Animal Health | 12.00 Bn | 11.47 Bn | 798.00 Mn | 36.60% |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.92 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.10 Bn | 5.57 Bn | 220.03 Mn | 15.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.25% |
| Mar 31, 2026 | 54.37% |
| Dec 31, 2025 | -46.87% |
| Sep 30, 2025 | -57.56% |
| Jun 30, 2025 | 41.65% |
| Mar 31, 2025 | 32.43% |
| Dec 31, 2024 | 42.15% |
| Sep 30, 2024 | 26.45% |
| Jun 30, 2024 | 55.09% |
| Mar 31, 2024 | 29.81% |
| Dec 31, 2023 | 9.89% |
| Sep 30, 2023 | 33.28% |
| Jun 30, 2023 | 32.59% |
| Mar 31, 2023 | 28.32% |
| Dec 31, 2022 | 57.66% |
| Sep 30, 2022 | 104.40% |
| Jun 30, 2022 | 24.97% |
| Mar 31, 2022 | 34.06% |
| Dec 31, 2021 | 24.17% |
| Sep 30, 2021 | 4.24% |